Natera, Inc. (NASDAQ:NTRA) Shares Sold by Cerity Partners LLC

Cerity Partners LLC cut its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 7.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 79,782 shares of the medical research company's stock after selling 6,362 shares during the period. Cerity Partners LLC owned about 0.06% of Natera worth $12,031,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in NTRA. Wilmington Savings Fund Society FSB bought a new position in shares of Natera during the 3rd quarter worth approximately $385,000. Everence Capital Management Inc. bought a new position in shares of Natera during the fourth quarter valued at $573,000. Smartleaf Asset Management LLC boosted its position in Natera by 50.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 657 shares of the medical research company's stock valued at $104,000 after buying an additional 220 shares in the last quarter. SeaBridge Investment Advisors LLC bought a new stake in Natera during the 4th quarter worth approximately $2,894,000. Finally, SYM FINANCIAL Corp bought a new position in shares of Natera in the fourth quarter valued at about $256,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on NTRA shares. BTIG Research reaffirmed a "buy" rating on shares of Natera in a research note on Friday, February 28th. The Goldman Sachs Group lifted their price target on shares of Natera from $160.00 to $190.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. Sanford C. Bernstein lifted their price objective on Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a research note on Friday, January 10th. Piper Sandler increased their target price on Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 4th. Finally, Robert W. Baird upped their price target on shares of Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a report on Friday, February 28th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, Natera currently has a consensus rating of "Moderate Buy" and an average target price of $175.76.

Remove Ads

Insider Transactions at Natera

In other news, CEO Steven Leonard Chapman sold 78,553 shares of Natera stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the completion of the sale, the chief executive officer now directly owns 267,629 shares of the company's stock, valued at approximately $44,150,756.13. The trade was a 22.69 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $140.48, for a total value of $421,440.00. Following the sale, the insider now directly owns 141,782 shares of the company's stock, valued at approximately $19,917,535.36. This trade represents a 2.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 325,922 shares of company stock valued at $51,603,664 over the last three months. Corporate insiders own 7.60% of the company's stock.

Natera Stock Up 1.5 %

NTRA traded up $2.15 during midday trading on Monday, hitting $150.19. The company had a trading volume of 490,534 shares, compared to its average volume of 1,392,930. The company has a market capitalization of $20.30 billion, a price-to-earnings ratio of -85.34 and a beta of 1.80. The stock's 50 day moving average price is $152.66 and its 200 day moving average price is $152.24. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 52 week low of $83.13 and a 52 week high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. On average, research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.